US Supreme Court agrees to hear Copaxone appeal

01-04-2014

US Supreme Court agrees to hear Copaxone appeal

Photo: Pavel Isupov / Shutterstock.com

The US Supreme Court has agreed to hear Teva’s appeal against a Federal Circuit decision that invalidated a patent covering its $4.3 billion-a-year Copaxone (glatiramer acetate) drug, allowing Sandoz, Mylan and Natco to produce generic versions.


Copaxone, Teva, US Supreme Court, appeal, Sandoz, Mylan, Natco

LSIPR